Sign in Subscribe
Universities and colleges

Identification of Tumor-Associated Phosphopeptides as Potential Targets for Cancer Immunotherapy

Strategic Insights

— 1 min read

A recent study from researchers at the University of Virginia has made a groundbreaking discovery that could revolutionize cancer treatment. The team, led by F.R. Depontieu, has identified tumor-associated phosphopeptides that can be targeted by CD4(+) T cells, providing a new avenue for cancer immunotherapy. These phosphopeptides, which are linked to proteins with vital cellular functions, may be the key to optimizing current cancer immunotherapy strategies and could potentially define cell type-specific "fingerprints" for different types of cancer.

Key Takeaways:

  • The study identified 175 HLA-DR-associated phosphopeptides in human cancer cells, many of which are derived from proteins involved in cancer development and growth.
  • These phosphopeptides are presented by human MHC II molecules and recognized by CD4(+) T cells, providing a new target for cancer immunotherapy.
  • The researchers generated HLA-DR beta 1*0101-restricted CD4(+) T cells specific for a phospho-MART-1 peptide, which showed specificity for phosphopeptide-pulsed antigen-presenting cells and intact melanoma cells.
  • The study provides evidence that phosphopeptides can serve as cell type-specific markers for different types of cancer, potentially leading to more targeted and effective cancer therapies.
  • The researchers conclude that their findings could lead to the development of new cancer immunotherapies that exploit the recognition of phosphopeptides by CD4(+) T cells.

Statistics:

  • 175 HLA-DR-associated phosphopeptides were characterized in the study.
  • Many of the phosphopeptides were derived from proteins involved in cancer development and growth.
  • The phosphopeptides were expressed exclusively by either melanomas or transformed B cells, suggesting their potential as cell type-specific markers.
  • The researchers generated CD4(+) T cells recognizing a phospho-MART-1 peptide, showing specificity for phosphopeptide-pulsed antigen-presenting cells and intact melanoma cells.

Sources:

  • F.R. Depontieu et al. "Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy." Proceedings of the National Academy of Sciences of the United States of America, 2009; 106(29): 12073-12078.

Read more